Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

This study has been completed.
Information provided by (Responsible Party):
Merck KGaA Identifier:
First received: September 8, 2005
Last updated: July 23, 2015
Last verified: July 2015
The primary objective is to document the safety of tecemotide (L-BLP25) phase III formulation in non-small cell lung cancer (NSCLC) subjects with unresectable Stage III disease. This population includes Stage IIIA NSCLC subjects, a population not studied in former clinical studies with this vaccine. The secondary objective is to document the survival of subjects treated.

Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Biological: Tecemotide (L-BLP25)
Drug: Single low dose cyclophosphamide
Other: Best standard of care (BSC)
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Patients With Unresectable Stage III Disease

Resource links provided by NLM:

Further study details as provided by Merck KGaA:

Primary Outcome Measures:
  • Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs With CALGB-ECTC Grade 3 or 4, TEAEs Leading to Discontinuation, TEAEs Leading to Death, and Injection Site Reactions (ISRs) [ Time Frame: Up to data cut-off date (17 September 2007) ] [ Designated as safety issue: Yes ]
    TEAEs occurred between the first dose of study drug and up to 42 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs with Cancer and Leukemia Group B Extended Clinical Toxicity Criteria (CALGB-ECTC) Grade 3 or 4 were also reported.

Secondary Outcome Measures:
  • Survival Time [ Time Frame: Up to data cut-off date (17 September 2007) ] [ Designated as safety issue: No ]
    Survival time was to be measured from study entry (date of cyclophosphamide administration) to date of death. For subjects alive or lost to follow-up at time of analysis, the time between date of cyclophosphamide administration and date on which the subject was last known alive was to be calculated and used as a censored observation in the analysis.

  • Progression Free Survival (PFS) Time [ Time Frame: Up to data cut-off date (17 September 2007) ] [ Designated as safety issue: No ]
    PFS was defined as duration from first administration of trial treatment until progressive disease [PD] (radiological or clinical, if radiological progression is not available) or death due to any cause. Participants without event were censored on the date of last tumor assessment. Clinical assessments were performed 4 weekly in primary treatment and 6 weekly in maintenance treatment.

Enrollment: 22
Study Start Date: April 2005
Study Completion Date: April 2012
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tecemotide(L-BLP25)+Cyclophosphomide+best standard of care Biological: Tecemotide (L-BLP25)
After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide [L-BLP25]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
Drug: Single low dose cyclophosphamide
A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
Other: Best standard of care (BSC)
The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically documented unresectable stage III NSCLC. Mediastinal (N2) involvement must be confirmed by biopsy
  • Stable disease or clinical response after primary therapy of chemo-radiation treatment for unresectable stage III disease
  • Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic radiation. The combined modality should consist of either:

    • induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy; or
    • concurrent chemo-radiation therapy followed by 2 cycles of consolidation chemotherapy; or
    • concurrent chemoradiation therapy alone
  • A minimum radiation dose of greater than or equal to (>=) 6,000 centigray (cGy) should be administered. Subjects must have completed the primary therapy at least 4 weeks and no later than 6 months prior to study entry
  • Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (<=) 1
  • Ability to understand and willingness to sign a written informed consent
  • Other protocol defined inclusion criteria could apply

Exclusion Criteria:

  • Undergone lung cancer specific therapy (including surgery) prior to primary chemo-radiation therapy
  • Received immunotherapy/systemic immunosuppressive drugs/investigational systemic drugs within 4 weeks prior to study entry
  • Subjects with brain metastases, pleural effusion, unless cytologically confirmed to be non-malignant
  • Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
  • Autoimmune disease or immunodeficiency
  • Clinically significant hepatic, renal dysfunction or cardiac diseases
  • Clinically significant active infection
  • Pregnant or lactating, women of childbearing potential, unless using effective contraception as determined by the investigator
  • Other protocol defined inclusion criteria could apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00157196

Sponsors and Collaborators
Merck KGaA
Study Director: Medical Responsible Merck KGaA
  More Information

Responsible Party: Merck KGaA Identifier: NCT00157196     History of Changes
Other Study ID Numbers: B25-LG-305 / EMR 63325-006
Study First Received: September 8, 2005
Results First Received: July 23, 2015
Last Updated: July 23, 2015
Health Authority: Canada: Health Canada

Keywords provided by Merck KGaA:
Carcinoma, Non-Small-Cell Lung, L-BLP25, Tecemotide

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 24, 2015